Non-Hodgkin Lymphoma (NHL)

Chimeric antigen receptor T-cell therapies, along with bispecific antibodies, have changed the treatment paradigm for patients with relapsed or refractory mantle cell lymphoma.

The FDA approved epcoritamab with rituximab and lenalidomide for relapsed follicular lymphoma, offering a promising fixed-duration treatment option for patients after their first relapse.

Routine flow cytometry can reliably track chimeric antigen receptor (CAR) T-cell expansion and persistence in aggressive large B-cell lymphoma (LBCL).

The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS, in relapsed/refractory LBCL.

New reporting suggests obesity and diffuse large B-cell lymphoma (DLBCL) have shared genetic risk factors.

Questions remain related to which patients with diffuse large B-cell lymphoma (DLBCL) benefit most from radiotherapy and at what dose.

A targeted therapy combination achieved complete remission in a CAR-positive PTCL patient post-CAR T-cell therapy for multiple myeloma.

Expanding clinical trial eligibility in slow-developing follicular lymphoma enhances patient access to innovative therapies and addresses healthcare disparities.

Outpatient treatment with axi-cel shows promising response rates for relapsed large B-cell lymphoma, enhancing accessibility in community oncology settings.

Zanubrutinib shows superior progression-free and overall survival in relapsed mantle cell lymphoma compared with acalabrutinib, according to a new analysis.

BeOne Medicines reveals promising results for sonrotoclax, a next-gen BCL2 inhibitor, in treating relapsed mantle cell lymphoma, addressing critical patient needs.

In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing financial toxicity and logistical barriers.

Study reveals one-third of mantle cell lymphoma patients in a study at leading cancer centers experienced disease progression after CAR T-cell therapy, highlighting treatment challenges and outcomes.

ImmunityBio's study reveals promising results for chemotherapy-free CD19 CAR NK cell therapy in treating Waldenström macroglobulinemia, offering hope for patients.

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in diffuse large B-cell lymphoma (DLBCL), enhancing precision medicine strategies.

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line treatment in newly diagnosed peripheral T-cell lymphoma (PTCL).

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.

Coverage from IVBM Cleveland, held May 15, 2025.

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell transplant or CAR T-cell therapy.

A post-hoc analysis of EPCORE-NHL-1 was presented at ASCO.

Subcutaneous mosunetuzumab shows promising efficacy and safety in high-tumor burden follicular lymphoma, paving the way for outpatient treatment options.